

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

Application Number	10/134,890- 661,905
Confirmation Number	5263
Filing Date	04/29/2002
First Named Inventor	Ji-In Kim Almstead
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	8543

SHEET 1 of 3

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (If known)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
Q	1	US-5,882,914	03/16/1999	Semenza	
	2	US-6,020,462	02/01/2000	Semenza	
	3	US-5,073,492	12/17/1991	Chen et al.	
	4	US-5,194,596	03/16/1993	Tischer et al.	
	5	US-5,219,739	06/15/1993	Tischer et al.	
	6	US-5,985,913	11/16/1999	Williams et al.	
	7	US-4,997,835	03/05/1991	Schaper et al.	
	8	US-5,942,527	08/24/1999	Kadaba et al.	
	9	US-6,329,378 B1	12/11/2001	Mei et al.	

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	CITE NO. <sup>1</sup>	FOREIGN PATENT DOCUMENT COUNTRY CODE <sup>4</sup> NUMBER <sup>4</sup> KIND CODE <sup>5</sup> (IF KNOWN)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T <sup>6</sup>
Q	10	WO 00/10578 A1	03/02/2000	The Johns Hopkins U. School of Medicine		
	11	WO 98/17267 A1	04/30/1998	ZymoGenetics, Inc.		
	12	WO 97/15308 A1	05/01/1997	ZymoGenetics, Inc.		
	13	WO 88/00047 A1	01/14/1988	Scripps Clinic and Research Foundation		
	14	EP 0315434 A2	05/10/1989	Yissum Research and Development Co. of the Hebrew U. of Jerusalem		
3	15	WO 02/16315 A1	02/28/2002	Merck Patent GMBH		

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	CITE NO. <sup>1</sup>	INCLUDE NAME OF THE AUTHOR (IN CAPITAL LETTERS), TITLE OF THE ARTICLE (WHEN APPROPRIATE), TITLE OF THE ITEM (BOOK, MAGAZINE, JOURNAL, SERIAL, SYMPOSIUM, CATALOG, ETC.), DATE, PAGE(S), VOLUME-ISSUE NUMBER(S), PUBLISHER, CITY AND/OR COUNTRY WHERE PUBLISHED	T <sup>6</sup>
6	16	BUN et al., "Oxygen Sensing and Molecular Adaptation of Hypoxia". Amer. Physiological Society, 1996, pp. 839-885, Vol. 76, No. 3.	
6	17	SEmenza, "Regulation of Mammalian O <sub>2</sub> Homeostasis by Hypoxia-Inducible Factor 1.", Annu. Rev. Cell Dev. Biol., 1999, pp. 551-578, Vol. 15.	

EXAMINER

DATE CONSIDERED

11/30/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (10-01)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/134,890 661, 905
		Confirmation Number	5263
		Filing Date	04/29/2002
		First Named Inventor	Ji-In Kim Almstead
		Group Art Unit	1614
		Examiner Name	
		Attorney Docket Number	8543

SHEET 2 of 3

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
Q	18	SHWEIKI et al., "Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis", <i>Proc. Natl. Acad. Sci.</i> , 1995, pp. 768-772, Vol. 92.	
	19	SEMENZA, "HIF-1: mediator of physiological and pathophysiological responses to hypoxia", <i>J. Appl. Physiol.</i> , 2000, pp. 1474-1480, Vol. 88.	
	20	SEMENZA, "Hypoxia-inducible factor 1: master regulator of O <sub>2</sub> homeostasis", <i>Genetics &amp; Development</i> , 1998, pp. 588-594, Vol. 8.	
	21	JIANG et al., "Transactivation and inhibitory domains of hypoxia-inducible factor 1α", <i>J. Biol. Chem.</i> , 1997, pp. 19253-19260, Vol. 272, No. 31.	
	22	JIANG et al., "Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1", <i>J. of Biol. Chem.</i> , 1996, pp. 17771-17778, Vol. 271, No. 30.	
	23	PEARLMAN et al., "Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis", <i>Nature Medicine</i> , 1995, pp. 1085-1089, Vol. 1, No. 10.	
	24	TAKESHITA et al., "A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model", <i>J. Clin. Invest.</i> , 1994, pp. 662-670, Vol. 93.	
	25	HENDEL et al., "Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion", <i>Circulation</i> , 2000, pp. 118-121, Vol. 101, No. 2.	
G	26	SCHWARTZ et al., "Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation", <i>J. Amer. College of Cardiology</i> , 2000, pp. 1323-1330, Vol. 35, No. 5.	
EXAMINER	BK	DATE CONSIDERED	11-30-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/134,890 661,905
		Confirmation Number	5263
		Filing Date	04/29/2002
		First Named Inventor	Ji-In Kim Almstead
		Group Art Unit	1614
		Examiner Name	
		Attorney Docket Number	8543
SHEET 3 of 3			

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	27	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis", <u>Letters to Nature</u> , 1992, pp. 843-845, Vol. 359.	
	28	LEVY et al., "Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia", <u>Drug Disc. Today</u> , 1995, pp. 13333-13340, Vol. 270, No. 22.	
	29	IKEDA et al., "Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells", <u>J. Biol. Chem.</u> , 1995, pp. 19761-19766, Vol. 270, No. 34.	
	30	LEVY et al., "Post-transcriptional regulation of vascular endothelial growth factor by hypoxia", <u>Drug Disc Today</u> , 1996, pp. 2746-2753, Vol. 271, No. 5.	
	31	AGANI et al., "Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity", <u>Mol. Pharmacol.</u> , 1998, pp. 749-754, Vol. 54.	
	32	BROGI et al., "Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only", <u>Circulation</u> , 1994, pp. 649-652, Vol. 90.	
	33	VAN BELLE et al., "Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor", <u>Circulation</u> , 1998, pp. 381-390, Vol. 97, No. 4.	
	34	SEmenza, "Regulation of erythropoietin production", <u>Hematol. Oncol. Clin. N. Amer.</u> , 1994, pp. 863-885, Vol. 8, No. 5.	
	35	SEmenza et al., "Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1", <u>J. Biol. Chem.</u> , 1994, pp. 23757-23763, Vol. 269, No. 38.	
	36	KRANZ, "Blood", <u>J. of Amer. Society of Hematology</u> , 1991, pp. 419-434, Vol. 77, No. 3.	
	37	QUROSHI et al., "Minicry of erythropoietin by a nonpeptide molecule", <u>PNAS</u> , 1999, pp. 12156-12161, Vol. 96, No. 21.	
EXAMINER	B. A.	DATE CONSIDERED	11-30-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.